Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial. The drug, an apoptosis signal-regulating ...

Results of another phase 2b study – called SYMMETRY – showed that efruxifermin was unable to hit its main objective as a treatment for patients with compensated cirrhosis (F4) due to NASH ...

It is the progressive form of non-alcoholic fatty liver disease (NAFLD). NASH can lead to cirrhosis and liver cancer.

It can lead to more severe conditions such as cirrhosis or liver cancer if untreated ... patients with moderate to advanced fibrosis due to NASH. The enthusiasm within the medical community ...